Is There an Optimal Choice in Refractory Colorectal Cancer? A Network Meta-Analysis

Andrea Casadei-Gardini; Alessandro Vagheggini; Fabio Gelsomino; Andrea Spallanzani; Paola Ulivi; Giulia Orsi; Giulia Rovesti; Kalliopi Andrikou; Emiliano Tamburini; Mario Scartozzi; Stefano Cascinu

doi:10.1016/j.clcc.2019.10.001

Is There an Optimal Choice in Refractory Colorectal Cancer? A Network Meta-Analysis

Andrea Casadei-Gardini, Alessandro Vagheggini, Fabio Gelsomino, Andrea Spallanzani, Paola Ulivi, Giulia Orsi, Giulia Rovesti, Kalliopi Andrikou, Emiliano Tamburini, Mario Scartozzi, Stefano Cascinu

Research output: Contribution to journal › Article › peer-review

Abstract

In the absence of head-to-head comparison studies, the present network meta-analysis evaluated and compared the efficacy of 4 therapeutic alternatives for refractory colorectal cancer. No difference in overall survival was found between regorafenib and TAS-102. Possible greater efficacy with TAS-102 compared with regorafenib was found for patients with a rectal primary location, performance status > 0, and age > 65 years. Regorafenib showed possible greater effectiveness for patients with performance status of 0 and age < 65 years. In the RAS wild-type population, the anti-EGFR drug showed superiority to TAS-102 and regorafenib. These results are only exploratory, and further prospective studies are warranted to validate these data.

Original language	English
Pages (from-to)	82-90.e9
Journal	Clinical Colorectal Cancer
Volume	19
Issue number	2
DOIs	https://doi.org/10.1016/j.clcc.2019.10.001
Publication status	Published - Jun 2020

Keywords

Anti-EGFR
Cetuximab
Metastatic colorectal cancer
Panitumumab
Regorafenib
TAS-102
Third-line therapy

ASJC Scopus subject areas

Oncology
Gastroenterology

Access to Document

10.1016/j.clcc.2019.10.001

Cite this

@article{aafd994ca7ba4838a1a42c3a1428bffa,

title = "Is There an Optimal Choice in Refractory Colorectal Cancer? A Network Meta-Analysis",

abstract = "In the absence of head-to-head comparison studies, the present network meta-analysis evaluated and compared the efficacy of 4 therapeutic alternatives for refractory colorectal cancer. No difference in overall survival was found between regorafenib and TAS-102. Possible greater efficacy with TAS-102 compared with regorafenib was found for patients with a rectal primary location, performance status > 0, and age > 65 years. Regorafenib showed possible greater effectiveness for patients with performance status of 0 and age < 65 years. In the RAS wild-type population, the anti-EGFR drug showed superiority to TAS-102 and regorafenib. These results are only exploratory, and further prospective studies are warranted to validate these data.",

keywords = "Anti-EGFR, Cetuximab, Metastatic colorectal cancer, Panitumumab, Regorafenib, TAS-102, Third-line therapy",

author = "Andrea Casadei-Gardini and Alessandro Vagheggini and Fabio Gelsomino and Andrea Spallanzani and Paola Ulivi and Giulia Orsi and Giulia Rovesti and Kalliopi Andrikou and Emiliano Tamburini and Mario Scartozzi and Stefano Cascinu",

year = "2020",

month = jun,

doi = "10.1016/j.clcc.2019.10.001",

language = "English",

volume = "19",

pages = "82--90.e9",

journal = "Clinical Colorectal Cancer",

issn = "1533-0028",

publisher = "Elsevier Inc.",

number = "2",

}

TY - JOUR

T1 - Is There an Optimal Choice in Refractory Colorectal Cancer? A Network Meta-Analysis

AU - Casadei-Gardini, Andrea

AU - Vagheggini, Alessandro

AU - Gelsomino, Fabio

AU - Spallanzani, Andrea

AU - Ulivi, Paola

AU - Orsi, Giulia

AU - Rovesti, Giulia

AU - Andrikou, Kalliopi

AU - Tamburini, Emiliano

AU - Scartozzi, Mario

AU - Cascinu, Stefano

PY - 2020/6

Y1 - 2020/6

N2 - In the absence of head-to-head comparison studies, the present network meta-analysis evaluated and compared the efficacy of 4 therapeutic alternatives for refractory colorectal cancer. No difference in overall survival was found between regorafenib and TAS-102. Possible greater efficacy with TAS-102 compared with regorafenib was found for patients with a rectal primary location, performance status > 0, and age > 65 years. Regorafenib showed possible greater effectiveness for patients with performance status of 0 and age < 65 years. In the RAS wild-type population, the anti-EGFR drug showed superiority to TAS-102 and regorafenib. These results are only exploratory, and further prospective studies are warranted to validate these data.

AB - In the absence of head-to-head comparison studies, the present network meta-analysis evaluated and compared the efficacy of 4 therapeutic alternatives for refractory colorectal cancer. No difference in overall survival was found between regorafenib and TAS-102. Possible greater efficacy with TAS-102 compared with regorafenib was found for patients with a rectal primary location, performance status > 0, and age > 65 years. Regorafenib showed possible greater effectiveness for patients with performance status of 0 and age < 65 years. In the RAS wild-type population, the anti-EGFR drug showed superiority to TAS-102 and regorafenib. These results are only exploratory, and further prospective studies are warranted to validate these data.

KW - Anti-EGFR

KW - Cetuximab

KW - Metastatic colorectal cancer

KW - Panitumumab

KW - Regorafenib

KW - TAS-102

KW - Third-line therapy

UR - http://www.scopus.com/inward/record.url?scp=85081682621&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85081682621&partnerID=8YFLogxK

U2 - 10.1016/j.clcc.2019.10.001

DO - 10.1016/j.clcc.2019.10.001

M3 - Article

C2 - 32192883

AN - SCOPUS:85081682621

VL - 19

SP - 82-90.e9

JO - Clinical Colorectal Cancer

JF - Clinical Colorectal Cancer

SN - 1533-0028

IS - 2

ER -

Is There an Optimal Choice in Refractory Colorectal Cancer? A Network Meta-Analysis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this